Navigation Links
Assessing lead time of selected ovarian cancer biomarkers
Date:12/30/2009

Concentrations of the biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of the National Cancer Institute. However, the biomarkers became substantially elevated only in the last year prior to diagnosis. The stage of the cancer at the time of marker elevation is not known.

CA125, HE4, mesothelin, B7-H4, decoy receptor 3, and spondin-2 have been identified as potential ovarian cancer biomarkers, but their behavior in the pre-diagnostic period, with the exception of CA125, has not been evaluated previously.

In this study, Garnet L. Anderson, Ph.D., of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center in Seattle, and colleagues analyzed stored serum samples from the Carotene and Retinol Efficacy Trial, a randomized, double-blind, placebo-controlled chemoprevention trial testing the effects of beta-carotene and retinol on lung cancer incidence among individuals at high risk for the disease. The researchers identified 34 patients who were diagnosed with ovarian cancer and had serum specimens available from the trial, as well as 70 matched control subjects.

Serum concentrations of CA125, HE4, and mesothelin began to increase slightly in cancer patients approximately 3 years before diagnosis but became substantially elevated only about a year before diagnosis.

These data suggest the presence of ovarian cancer up to 3 years before clinical diagnosis, but the likely lead time associated with these markers appears to be less than 1 year, according to the authors.

"Although these markers are not accurate enough to prompt early intervention in existing screening protocols, the multivariable regression analyses identified modest but statistically significant increases in risk associated with CA125, HE4, and mesothelin, which are consist
'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Breakthrough made in assessing marine phytoplankton health
2. Lighting research center develops framework for assessing light pollution
3. Research identifies first method for testing, assessing drug treatments for Chagas disease
4. BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine
5. BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine
6. Ph.D. student in K-State plant pathology selected for international fellowship
7. ComCam Selected by ePortation on New Maritime Domain Awareness Project
8. M2SYS Biometric Software Solution Selected By GHG Corporation
9. UC Riverside student is 1 of only 5 persons selected for challenging Arctic expedition
10. ComCam Selected by ePortation on New Maritime Domain Awareness Project
11. Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the ... Second quarter contract revenue of $ 85.2 ... contract margins of 26 % , Second ... EPS from royalties in the current quarter , ... very pleased to present another strong financial quarter, with all our ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... St. Louis, July 31, 2008 Staying awake slows down ... its peak after sleep but inevitably trends downward throughout the ... For the first time, researchers at Washington University School of ... this downward slide. When scientists genetically tweaked a part of ...
... Michigan State University researcher and his students have ... and stronger and could result in more fuel-efficient ... medical and sports equipment. The material ... in the development of new and expanded applications ...
... Auckland, New Zealand - Kiwifruit lovers can look forward ... to the release this week of crucial genetic data ... new varieties with increased health properties and exciting colours ... company HortResearch and listed New Zealand biotech company Genesis ...
Cached Biology News:Brain tweak lets sleep-deprived flies stay sharp 2'Small' research at MSU leads to advances in energy, electronics 2Genetic data promises new future for kiwi fruit 2Genetic data promises new future for kiwi fruit 3
(Date:8/31/2015)...  US-Australian drug discovery company, Novogen Limited (ASX: ... comprehensive scientific review has identified high value opportunities ... unmet patient need. Novogen is moving as quickly ... to entering into Phase 1 clinical trials with ... Executive Officer, Iain Ross , said that ...
(Date:8/31/2015)... Trimb Healthcare AB ("Trimb") today announced that it has ... a Dutch OTC company with operations in key European ... 16 million, with solid growth and leading brands in ... build a leading international OTC company, and this acquisition ... us a stronger North European OTC platform, from which ...
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a ... Annual High Tech Awards. , Now in its 22nd year, this premier awards ... innovation here, across the nation and around the world. The OC Tech Alliance will ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... presented two studies at the International Spine Intervention Society’ s 23rd ... through to August 1st, 2015. With a focus on evidence-based research and clinical ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4
... may seem obvious that dunking relatively spherical objects in ... will result in an array of completely encapsulated berries. ... have similarly dunked their wares in protective coatings in ... chemical interactions with solvents. Unfortunately, reactions in the ...
... Beta-Pro LLC, announced today that it has expanded ... drug discovery and research institutes in the $2 ... now manages extensive laboratory facilities in the University ... "Beta-Pro has already established a foothold ...
... US Oncology, Inc., the nation,s leading integrated oncology ... patient in a Phase I clinical trial through its ... trials present special challenges, including increased safety concerns, higher ... some first-in-human trials, making Phase I trials more difficult ...
Cached Biology Technology:Nanoscopic particles resist full encapsulation, Sandia simulations show 2Beta-Pro Expands Operations to Meet Demands for Human Cells in Hepatocyte Drug Discovery Market 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5
Human Legumain Affinity Purified Polyclonal Ab...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Human Cystatin F MAb (Clone 292103)...
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
Biology Products: